Edwards Lifesciences Corp (NYSE:EW) VP Sells $79,805.16 in Stock

Edwards Lifesciences Corp (NYSE:EW) VP Catherine M. Szyman sold 372 shares of the company’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $214.53, for a total transaction of $79,805.16. Following the completion of the sale, the vice president now directly owns 18,010 shares in the company, valued at $3,863,685.30. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

EW traded up $4.13 on Friday, reaching $219.34. The company had a trading volume of 1,076,700 shares, compared to its average volume of 1,186,510. Edwards Lifesciences Corp has a fifty-two week low of $136.44 and a fifty-two week high of $220.48. The stock has a market cap of $45.62 billion, a P/E ratio of 46.67, a P/E/G ratio of 2.69 and a beta of 0.87. The company’s fifty day moving average is $201.89 and its 200 day moving average is $185.13. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.48 and a current ratio of 3.38.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $1.38 EPS for the quarter, beating the Zacks’ consensus estimate of $1.33 by $0.05. Edwards Lifesciences had a net margin of 18.29% and a return on equity of 31.25%. The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the prior year, the business earned $1.24 EPS. Edwards Lifesciences’s quarterly revenue was up 15.2% on a year-over-year basis. On average, sell-side analysts expect that Edwards Lifesciences Corp will post 5.34 EPS for the current year.

Several large investors have recently made changes to their positions in EW. Nuveen Asset Management LLC grew its position in shares of Edwards Lifesciences by 8,278.5% during the 2nd quarter. Nuveen Asset Management LLC now owns 3,951,568 shares of the medical research company’s stock worth $730,013,000 after purchasing an additional 3,904,405 shares in the last quarter. Jennison Associates LLC grew its position in shares of Edwards Lifesciences by 40.2% during the 1st quarter. Jennison Associates LLC now owns 5,763,824 shares of the medical research company’s stock worth $1,102,792,000 after purchasing an additional 1,651,691 shares in the last quarter. BlackRock Inc. grew its position in shares of Edwards Lifesciences by 4.7% during the 1st quarter. BlackRock Inc. now owns 17,211,498 shares of the medical research company’s stock worth $3,293,075,000 after purchasing an additional 780,079 shares in the last quarter. FMR LLC grew its position in shares of Edwards Lifesciences by 7.9% during the 1st quarter. FMR LLC now owns 8,175,796 shares of the medical research company’s stock worth $1,564,274,000 after purchasing an additional 598,976 shares in the last quarter. Finally, Bessemer Group Inc. grew its position in shares of Edwards Lifesciences by 56,300.0% during the 2nd quarter. Bessemer Group Inc. now owns 503,652 shares of the medical research company’s stock worth $93,045,000 after purchasing an additional 502,759 shares in the last quarter. Hedge funds and other institutional investors own 82.43% of the company’s stock.

A number of brokerages have recently issued reports on EW. Credit Suisse Group upped their target price on shares of Edwards Lifesciences from $221.00 to $226.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Wells Fargo & Co upped their target price on shares of Edwards Lifesciences from $207.00 to $220.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. JPMorgan Chase & Co. upped their target price on shares of Edwards Lifesciences from $190.00 to $225.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. BMO Capital Markets upped their target price on shares of Edwards Lifesciences from $204.00 to $224.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Finally, Jefferies Financial Group upped their target price on shares of Edwards Lifesciences from $210.00 to $245.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $204.74.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Further Reading: Bond

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.